Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositis

Arthritis Research and Therapy

Volumn 15, Issue 4, 2013, Pages

  Alemo Munters, Li ^a   Dastmalchi, Maryam ^a   Katz, Abram ^b,c   Esbjörnsson, Mona ^b   Loell, Ingela ^a   Hanna, Balsam ^d   Lidén, Maria ^e   Westerblad, Håkan ^b   Lundberg, Ingrid E ^a   Alexanderson, Helene ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c ARIEL UNIVERSITY   (Israel)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A DEHYDROGENASE; BETA HYDROACYL COENZYME A DEHYDROGENASE; CITRATE SYNTHASE; CYCLOSPORIN A; GLUCOCORTICOID; LACTIC ACID; METHOTREXATE; MITOCHONDRIAL ENZYME; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; AEROBIC CAPACITY; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROL GROUP; CONTROLLED STUDY; CYCLING; DERMATOMYOSITIS; ENDURANCE TRAINING; ENZYME ACTIVITY; EXERCISE; EXHAUSTION; FEMALE; HEALTH STATUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LACTATE BLOOD LEVEL; MALE; MICRODIALYSIS; MUSCLE BIOPSY; MUSCLE MITOCHONDRION; MUSCLE WEAKNESS; OXYGEN CONSUMPTION; POLYMYOSITIS; RANDOMIZED CONTROLLED TRIAL; VASTUS LATERALIS MUSCLE; CLINICAL TRIAL; ENDURANCE; EXERCISE TOLERANCE; KINESIOTHERAPY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHYSIOLOGY; PROCEDURES; SKELETAL MUSCLE;

ADULT; AGED; DERMATOMYOSITIS; EXERCISE; EXERCISE THERAPY; EXERCISE TOLERANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; PHYSICAL ENDURANCE; POLYMYOSITIS;

EID: 84881293382     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4263     Document Type: Article

References (43)

1. Hengstman GJ, van den Hoogen FH, van Engelen BG. Treatment of the inflammatory myopathies: update and practical recommendations. Expert Opin Pharmacother 2009, 10:1183-1190. 10.1517/14656560902913815, 19405792.
2. Harris-Love MO, Shrader JA, Koziol D, Pahlajani N, Jain M, Smith M, Cintas HL, McGarvey CL, James-Newton L, Pokrovnichka A, Moini B, Cabalar I, Lovell DJ, Wesley R, Plotz PH, Miller FW, Hicks JE, Rider LG. Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis. Rheumatology (Oxford) 2009, 48:134-139.
3. Rayavarapu S, Coley W, Nagaraju K. An update on pathogenic mechanisms of inflammatory myopathies. Curr Opin Rheumatol 2011, 23:579-584. 10.1097/BOR.0b013e32834b41d2, 21960036.
4. Henriques-Pons A, Nagaraju K. Nonimmune mechanisms of muscle damage in myositis: role of the endoplasmic reticulum stress response and autophagy in the disease pathogenesis. Curr Opin Rheumatol 2009, 21:581-587. 10.1097/BOR.0b013e3283319265, 2877394, 19713850.
5. Zong M, Lundberg IE. Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol 2011, 7:297-306. 10.1038/nrrheum.2011.39, 21468145.
6. Alexanderson H, Lundberg IE. Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies. Curr Opin Rheumatol 2012, 24:201-207. 10.1097/BOR.0b013e32834f19f5, 22189517.
7. Miller FW. New approaches to the assessment and treatment of the idiopathic inflammatory myopathies. Ann Rheumatic Dis 2012, 71(Suppl 2):i82-85.
8. Park JH, Olsen NJ. Utility of magnetic resonance imaging in the evaluation of patients with inflammatory myopathies. Curr Rheumatol Rep 2001, 3:334-345. 10.1007/s11926-001-0038-x, 11470053.
9. Dastmalchi M, Alexanderson H, Loell I, Stahlberg M, Borg K, Lundberg IE, Esbjornsson M. Effect of physical training on the proportion of slow-twitch type I muscle fibers, a novel nonimmune-mediated mechanism for muscle impairment in polymyositis or dermatomyositis. Arthritis Rheum 2007, 57:1303-1310. 10.1002/art.22996, 17907213.
10. Loell I, Helmers SB, Dastmalchi M, Alexanderson H, Munters LA, Nennesmo I, Lindroos E, Borg K, Lundberg IE, Esbjörnsson M. Higher proportion of fast-twitch (type II) muscle fibres in idiopathic inflammatory myopathies-evident in chronic but not in untreated newly diagnosed patients. Clin Physiol Funct Imaging 2011, 31:18-25. 10.1111/j.1475-097X.2010.00973.x, 21029327.
11. Wiesinger GF, Quittan M, Nuhr M, Volc-Platzer B, Ebenbichler G, Zehetgruber M, Graninger W. Aerobic capacity in adult dermatomyositis/polymyositis patients and healthy controls. Arch Phys Med Rehabil 2000, 81:1-5. 10.1016/S0003-9993(00)90212-0, 10638867.
12. Cea G, Bendahan D, Manners D, Hilton-Jones D, Lodi R, Styles P, Taylor DJ. Reduced oxidative phosphorylation and proton efflux suggest reduced capillary blood supply in skeletal muscle of patients with dermatomyositis and polymyositis: a quantitative 31P-magnetic resonance spectroscopy and MRI study. Brain 2002, 125:1635-1645. 10.1093/brain/awf163, 12077012.
13. Grundtman C, Tham E, Ulfgren AK, Lundberg IE. Vascular endothelial growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositis. Arthritis Rheum 2008, 58:3224-3238. 10.1002/art.23884, 18821695.
14. Probst-Cousin S, Neundörfer B, Heuss D. Microvasculopathic neuromuscular diseases: lessons from hypoxia-inducible factors. Neuromuscul Disord 2010, 20:192-197. 10.1016/j.nmd.2010.01.005, 20122829.
15. Habers GE, Takken T. Safety and efficacy of exercise training in patients with an idiopathic inflammatory myopathy - a systematic review. Rheumatology (Oxford) 2011, 50:2113-2124.
16. Nader GA, Lundberg IE. Exercise as an anti-inflammatory intervention to combat inflammatory diseases of muscle. Curr Opin Rheumatol 2009, 21:599-603. 10.1097/BOR.0b013e3283319d53, 19726993.
17. Wiesinger GF, Quittan M, Aringer M, Seeber A, Volc-Platzer B, Smolen J, Graninger W. Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme. Br J Rheumatol 1998, 37:196-200. 10.1093/rheumatology/37.2.196, 9569076.
18. Nader GA, Dastmalchi M, Alexanderson H, Grundtman C, Gernapudi R, Esbjornsson M, Wang Z, Ronnelid J, Hoffman EP, Nagaraju K, Lundberg IE. A longitudinal, integrated, clinical, histological and mRNA profiling study of resistance exercise in myositis. Mol Med 2010, 16:455-464. 2972393, 20809047.
19. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292:344-347. 10.1056/NEJM197502132920706, 1090839.
20. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975, 292:403-407. 10.1056/NEJM197502202920807, 1089199.
21. Borg GA. Perceived exertion. Exerc Sport Sci Rev 1974, 2:131-153.
22. Lundberg G, Olofsson P, Ungerstedt U, Jansson E, Sundberg CJ. Lactate concentrations in human skeletal muscle biopsy, microdialysate and venous blood during dynamic exercise under blood flow restriction. Pflugers Arch 2002, 443:458-465. 10.1007/s004240100706, 11810217.
23. Dorph C, Nennesmo I, Lundberg IE. Percutaneous conchotome muscle biopsy. A useful diagnostic and assessment tool. J Rheumatol 2001, 28:1591-1599.
24. Holloszy JO, Coyle EF. Adaptations of skeletal muscle to endurance exercise and their metabolic consequences. J Appl Physiol 1984, 56:831-838.
25. Reisch AS, Elpeleg O. Biochemical assays for mitochondrial activity: assays of TCA cycle enzymes and PDHc. Methods Cell Biol 2007, 80:199-222.
26. Alp PR, Newsholme EA, Zammit VA. Activities of citrate synthase and NAD+-linked and NADP+-linked isocitrate dehydrogenase in muscle from vertebrates and invertebrates. Biochem J 1976, 154:689-700. 1172771, 8036.
27. Bass A, Brdiczka D, Eyer P, Hofer S, Pette D. Metabolic differentiation of distinct muscle types at the level of enzymatic organization. Eur J Biochem 1969, 10:198-206. 10.1111/j.1432-1033.1969.tb00674.x, 4309865.
28. Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, Oddis C, Pilkington C, Plotz P, Scott D, Vencovsky J, Cooper R, Rider L, Miller F, . International Myositis and Clinical Studies Group (IMACS) International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004, 43:49-54. International Myositis and Clinical Studies Group (IMACS).
29. Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, Lundberg I, Morrison C, Oakley L, Oakley I, Pilkington C, Vencovsky J, Vincent K, Scott DL, Isenberg DA, . International Myositis Outcome Assessment Collaborative Study Group Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 2001, 40:1262-1273. International Myositis Outcome Assessment Collaborative Study Group.
30. Sultan SM, Allen E, Oddis CV, Kiely P, Cooper RG, Lundberg IE, Vencovsky J, Isenberg DA. Reliability and validity of the myositis disease activity assessment tool. Arthritis Rheum 2008, 58:3593-3599. 10.1002/art.23963, 18975333.
31. Sultan SM, Allen E, Cooper RG, Agarwal S, Kiely P, Oddis CV, Vencovsky J, Lundberg IE, Dastmalchi M, Hanna MG, Isenberg DA. Interrater reliability and aspects of validity of the myositis damage index. Ann Rheum Dis 2011, 70:1272-1276. 10.1136/ard.2010.142117, 21622773.
32. Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, Lachenbruch PA, Miller FW. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004, 50:2281-2290. 10.1002/art.20349, 15248228.
33. Paulus HE, Egger MJ, Ward JR, Williams HJ. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. Arthritis Rheum 1990, 33:477-484. 10.1002/art.1780330403, 2109613.
34. McComas AJ, Miller RG, Gandevia SC. Fatigue brought on by malfunction of the central and peripheral nervous systems. Adv Exp Med Biol 1995, 384:495-512. 10.1007/978-1-4899-1016-5_38, 8585475.
35. Alemo Munters L, van Vollenhoven RF, Alexanderson H. Patient preference assessment reveals disease aspects not covered by recommended outcomes in polymyositis and dermatomyositis. ISRN Rheumatol 2011, 2011:463124. 3263738, 22389795.
36. Alexanderson H, Reed AM, Ytterberg SR. The myositis activities profile-initial validation for assessment of polymyositis/dermatomyositis in the USA. J Rheumatol 2012, 39:2134-2141. 10.3899/jrheum.120504, 22942260.
37. Harty LC, Biniecka M, O'Sullivan J, Fox E, Mulhall K, Veale DJ, Fearon U. Mitochondrial mutagenesis correlates with the local inflammatory environment in arthritis. Ann Rheum Dis 2012, 71:582-588. 10.1136/annrheumdis-2011-200245, 22121133.
38. Mitsui T, Azuma H, Nagasawa M, Iuchi T, Akaike M, Odomi M, Matsumoto T. Chronic corticosteroid administration causes mitochondrial dysfunction in skeletal muscle. J Neurol 2002, 249:1004-1009. 10.1007/s00415-002-0774-5, 12195445.
39. Hasselgren PO. Glucocorticoids and muscle catabolism. Curr Opin Clin Nutr Metab Care 1999, 2:201-205. 10.1097/00075197-199905000-00002, 10456248.
40. Fitts RH, Romatowski JG, Peters JR, Paddon-Jones D, Wolfe RR, Ferrando AA. The deleterious effects of bed rest on human skeletal muscle fibers are exacerbated by hypercortisolemia and ameliorated by dietary supplementation. Am J Physiol Cell Physiol 2007, 293:C313-320. 10.1152/ajpcell.00573.2006, 17409123.
41. Wiesinger GF, Quittan M, Graninger M, Seeber A, Ebenbichler G, Sturm B, Kerschan K, Smolen J, Graninger W. Benefit of 6 months long-term physical training in polymyositis/dermatomyositis patients. Br J Rheumatol 1998, 37:1338-1342. 10.1093/rheumatology/37.12.1338, 9973161.
42. Dalise S, Bertolucci F, Simonella C, Rossi B, Chisari C. Intensive aerobic training improves motor performances and oxidative metabolism efficiency in chronic polymyositis: a case report. Neuromuscul Disord 2012, 22:S221-S225.
43. Alexanderson H, Dastmalchi M, Esbjornsson-Liljedahl M, Opava CH, Lundberg IE. Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis Rheum 2007, 57:768-777. 10.1002/art.22780, 17530676.